ARK Genomic Revolution ETF vs Oscar Health Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.46, while Oscar Health Inc trades at $29.03 (market cap $8.63B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Oscar Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | OSCR | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $44.55 | $32.18 |
52-Week Low | $24.02 | $10.85 |
Market Cap | — | $8.63B |
Enterprise Value | — | $4.99B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Oscar Health (OSCR) trades at $29.11, up 5.2% with strong recent earnings momentum, beating estimates in Q1 and Q2 2026. The stock shows bearish technical signals but benefits from record profitability and raised 2026 guidance. Revenue surged 70% to $4.9 billion in H1 2026, with net income turning positive at $551 million versus a 2025 loss. Valuation remains attractive with P/S of 0.53, suggesting potential undervaluation versus sector peers.
Outlook is positive given membership growth and cost discipline, but risks include medical cost volatility and competitive pressures. Analyst consensus price target of $32.50 implies 12% upside, though technical resistance near $30 may limit near-term gains. Execution on guidance and sustained margin expansion are key catalysts.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →